Search Results

Daniel M. Geynisman, MD, is being announced as the new Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network.

The National Comprehensive Cancer Network® is announcing 2024 award recipients that include individuals and groups who have made significant and noteworthy impacts on improving cancer care and supporting NCCN’s mission to help all people with cancer to live better lives.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it will present a poster at the National Comprehensive Cancer Network (NCCN) 2024 Annual Conference, which will be held April 5-7, 2024, in Orlando, Florida.

TerSera Therapeutics LLC announced today that The National Comprehensive Cancer Network® (NCCN) Breast Cancer Panel included both goserelin 3.6 mg every 4 weeks and goserelin 10.8 mg every 12 weeks, as methods for ovarian function suppression in Version 1.2024 of the Breast Guidelines revised as of January 25, 2024.

TerSera Therapeutics LLC announced that The National Comprehensive Cancer Network® Head and Neck Cancers Panel included a category 2B recommendation for goserelin as useful, in certain circumstances, for recurrent, unresectable, or metastatic salivary gland tumors in Version 1.2024 of the Head and Neck Cancers Guidelines released on October 9, 2023.

Ascentage Pharma announced that olverembatinib has been included in the latest guidelines from the National Comprehensive Cancer Network for the management of Chronic Myeloid Leukemia,[1] marking a major development in global recognition for its best-in-class drug candidate, which has been approved in China for the management of tyrosine kinase inhibitor -resistant patients with chronic- and accelerated-phase CML.

The National Comprehensive Cancer Network announced the publication of a new supportive care patient guideline focused on preventing and treating cancer-associated blood clots, also known as venous thromboembolism.